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Abstract
T cells play a critical role in controlling viral infection; however, the mechanisms regulating their responses remain
incompletely understood. Here, we investigated the role of topoisomerase IIA (Top2α, an enzyme that is essential in
resolving entangled DNA strands during replication) in telomeric DNA damage and T cell dysfunction during viral
infection. We demonstrated that T cells derived from patients with chronic viral (HBV, HCV, and HIV) infection had
lower Top2α protein levels and enzymatic activity, along with an accumulation of the Top2α cleavage complex
(Top2cc) in genomic DNA. In addition, T cells from virally infected subjects with lower Top2α levels were vulnerable to
Top2α inhibitor-induced cell apoptosis, indicating an important role for Top2α in preventing DNA topological
disruption and cell death. Using Top2α inhibitor (ICRF193 or Etoposide)-treated primary T cells as a model, we
demonstrated that disrupting the DNA topology promoted DNA damage and T cell apoptosis via Top2cc
accumulation that is associated with protein-DNA breaks (PDB) at genomic DNA. Disruption of the DNA topology was
likely due to diminished expression of tyrosyl-DNA phosphodiesterase 2 (TDP2), which was inhibited in T cells in vitro
by Top2α inhibitor and in vivo by chronic viral infection. These results suggest that immune-evasive viruses (HBV, HCV,
and HIV) can disrupt T cell DNA topology as a mechanism of dysregulating host immunity and establishing chronic
infection. Thus, restoring the DNA topologic machinery may serve as a novel strategy to protect T cells from unwanted
DNA damage and to maintain immune competence.

Introduction
T cells play a critical role in control of viral infection. In
studying the role of T cell dysregulation in viral persistence in humans, we and others have previously shown
that chronic viral infections can cause premature T cell
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aging and immune senescence, as evidenced by the
expression of aging markers and particularly, accumulation of DNA damage1–17. However, the underlying
mechanisms remain unclear.
Given the nature of two intertwined DNA strands in
chromosomes, almost all types of DNA activities,
including gene replication, transcription, and recombination, can lead to topological entanglements that must
be resolved to ensure genetic code normal transactions
and cellular functions18–20. In order to prevent and correct these topological problems, topoisomerases bind to
and cut the DNA strands, allowing the DNA to be
untangled, and after that, the DNA backbone is resealed.
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Failure to complete this catalytic process results in
topoisomerase trapping on the DNA termini, forming
topoisomerase cleavage complex (TOPcc), and generating
protein-linked DNA breaks (PDB), a frequent event that
occurs to induce cell apoptosis21,22. There are three main
types of topology: supercoiling, knotting, and catenation.
Correspondingly, the human genome encodes three types
of topoisomerases (type IA, type IB, and type IIA) to
resolve such DNA entanglements. Notably, the insertion
of viral or bacterial DNA into host chromosomes also
requires the action of topoisomerases. Many drugs, such
as broad-spectrum ﬂuoroquinolone antibiotics and chemotherapy drugs, operate through interference with the
topoisomerases of bacteria or cancer cells and create PDB
in chromosomal DNA that promote cell apoptosis or
dysfunction23–25. Thus, although DNA topology is crucial
for normal cell functions, its disruption may lead to DNA
damage response (DDR) and cell death.
While inhibition of topoisomerases has been widely
exploited to kill bacteria and cancer cells23,24, the role and
mechanisms of topoisomerase in reprogramming DDR
and altering the function of T lymphocytes, especially in
the context of chronic viral infection, remain largely
unknown. We have recently shown that topoisomerase I
(Top1) is inhibited and causes topological DNA damage
and T cell senescence during chronic viral infections9.
Here we further demonstrate that Topoisomerase IIA
(Top2α) is signiﬁcantly inhibited and plays a critical role
in reprogramming DDR and remodeling T cell function
or apoptosis during chronic viral infections.

Results
Top2α expression and activity are inhibited in CD4 T cells
during chronic viral infections

Top2α is critical in unraveling the entangled DNA to
prevent unwanted DNA damage and cell death21. As an
initial approach to explore the role of Top2α in DNA
damage and T cell apoptosis, we examined the levels of
Top2α in CD4 T cells derived from individuals with
chronic viral (HCV, HBV, HIV) infections. Since Top2a is
only expressed in activated T cells, we examined Top2a
expression in puriﬁed CD4 T cells stimulated with antiCD3/CD28 for 3 days, followed by western blotting. As
shown in Fig. 1a, chronically HBV, HCV, or HIV-infected
individuals exhibited a lower level of Top2α expression in
CD4 T cells compared to age-matched healthy subjects
(HS). To determine whether Top2α inhibition occurs at
the transcriptional or post-transcriptional level, we measured Top2α mRNA by RT-PCR in CD4 T cells derived
from the same subjects. As shown in Fig. 1b, the mRNA
levels of Top2α in CD4 T cells isolated from virusinfected patients remained unchanged compared to HS,
indicating that Top2α inhibition occurs primarily at the
post-transcriptional level during viral infection.
Ofﬁcial journal of the Cell Death Differentiation Association
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In addition to the Top2α expression, we employed a
kDNA-based Top II Assay to measure Top2α activity. We
found that the catenated kDNA was extremely large and
could not migrate through a 1% agarose gel without being
relaxed. In contrast, the monomeric DNA (2.5 kb) rapidly
migrated through the gel as nicked open circular or fully
closed circular rings. After optimizing concentrations of
nuclear extracts, we compared Top2α activity using
nuclear extracts from CD4 T cells isolated from virally
infected subjects and HS. As shown in Fig. 1c left panel,
the linear kDNA (lane 1) and Top2α-relaxed kDNA (lane
2) served as a positive control and the kDNA treated with
nuclear extracts of non-stimulated HS T cells served as a
negative control (lane 3). The kDNA treated with the
optimal concentration of nuclear extracts from T cell
receptor (TCR)-stimulated T cells showed varying
amounts of decatenated, closed circular DNA, and virally
infected patients’ samples (lane 5–7) had lower efﬁciency
in relaxing kDNA compared to HS (lane 4). The relative
Top2α activity in CD4 T cells derived from HBV, HCV,
and HIV-infected individuals (normalized to HS) was
summarized and is shown in Fig. 1c right panel and shows
that Top2α activity is inhibited in T cells during chronic
viral infection.
To determine if Top2α inhibition results in Top2cc
accumulation and entrapment in T cell chromosomes, we
measured chromatin-associated Top2cc from CD4 T cells
of virally infected patients by immunoblotting with a
monoclonal antibody that speciﬁcally recognizes covalent
Top2α-DNA complexes. As shown in Fig. 1d, an
increased amount of Top2cc was detected in the genomic
DNA of CD4 T cells isolated from HBV, HCV, and HIVinfected patients compared to HS. These results suggest
that T cells from virus-infected patients have DNA
topological problems, i.e., Top2α inhibition and Top2cc
accumulation.
Top2α inhibition leads to T cell apoptosis or dysfunction

To determine the consequence of Top2α inhibition, we
employed two distinct Top2α-targeting compounds in
this study: Top2α poison Etoposide (ETP), which binds to
and stabilizes Top2cc to prevent DNA religation and
generate PDB; and Top2α catalytic inhibitor ICRF-193,
which inhibits ATP hydrolysis after strand passage and
religation and before the closed clamp conformation
reopens24–29. Here, we employed Top2α inhibitor-treated
primary CD4 T cells as a model to study the role and
mechanisms of Top2α in T cell dysregulation. We ﬁrst
assessed the Top2α level in T cells treated with Top2α
inhibitors. As shown in Fig. 2a, b, Top2α protein was not
detectable in resting primary CD4 T cells but was
detected at 48 h after T cell stimulation. TCR-stimulated
CD4 T cells showed Top2α inhibition by ICRF or ETP
when compared to the DMSO-treated control. Also,
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Fig. 1 Inhibition of Top2α expression and activity in CD4 T cells during chronic viral infections. a Top2α protein expression in CD4 T cells
isolated from HBV, HCV, and HIV-infected individuals and healthy subjects (HS). Representative images and summary data of western blot are shown.
The Top2α band intensity (lower panel) was normalized to β-actin and is presented relative to HS (n = number of subjects). b Top2α mRNA levels,
determined by RT-qPCR, in CD4 T cells isolated from virally infected individuals and HS. c Top2α activity in CD4 T cells isolated from HBV, HCV, and
HIV-infected individuals and HS. Representative images and summary data of Top2α-mediated digestion of kDNA substrate (normalized to TCRstimulated HS control) are shown (n = number of subjects tested). d Top2cc was detected in genomic DNA isolated from CD4 T cells of virus-infected
patients versus HS.

Top2α inhibitor-treated CD4 T cells exhibited considerable Top2cc accumulation in their genomic DNA (Fig. 2c).
These results indicate that Top2α inhibition and Top2cc
accretion in CD4 T cells treated with ICRF and ETP
recapitulate our ﬁndings in CD4 T cells derived from
virus-infected individuals.
We next measured the effect of Top2α inhibition on
cellular functions. To this end, CD4 T cells were isolated
from HS and exposed to various concentrations (0, 0.05,
0.1, 0.2, 0.5, 1 μM) of ETP in the presence of TCR stimulation for 3 days, followed by measuring intracellular
IL-2 and IFN-γ production by ﬂow cytometry. As shown
in Fig. 2d, IL-2 and IFN-γ productions were inhibited in a
dose-dependent manner in CD4 T cells exposed to ETP.
Also, a signiﬁcant inhibition of T cell proliferation,
determined by CFSE dilution in CD4 T cells, was
observed in T cells exposed to ICRF compared to control
with TCR stimulation (Fig. 2e). In addition, we measured
apoptosis of CD4 T cells exposed to various doses (0, 2, 4,
or 8 μg/ml) of ICRF for different times (0, 1, 2, 3, or
5 days) in the presence of anti-CD3/CD28 (1 μg/ml) by
ﬂow cytometry analysis. As shown in Fig. 2f, ICRF-treated
T cells exhibited time-dependent increases in Annexin V
(Av) and 7-Aminoactinomycin D (7AAD) staining compared to the DMSO-treated control.
Since T cells from virally infected patients exhibited
lower levels of Top2α and enzymatic activity, we
Ofﬁcial journal of the Cell Death Differentiation Association

hypothesized that these cells are more vulnerable to
Top2α inhibitor-mediated cell apoptosis. We thus compared the apoptotic susceptibility of CD4 T cells derived
from virus-infected patients and age-matched HS following ICRF treatment. Indeed, CD4 T cells isolated from
HBV, HCV, and HIV-infected patients exhibited higher
rates of cell apoptosis (Av+) and death (7-AAD+) upon
exposure to a Top2α inhibitor compared to cells from HS
(Fig. 2g). Taken together, these results suggest that Top2α
inhibition can cause T cell apoptosis or dysfunction,
highlighting the role of Top2α in securing T cell survival
and function, and providing a robust model to study
topological DNA damage in human T cell dysregulation.
Top2α inhibition induces cell apoptosis by enhancing
topological DNA damage that extends to telomeres

To determine if topological DNA damage is a major cause
of T cell apoptosis, we treated primary CD4 T cells with
ICRF-193 or DMSO in the presence of TCR stimulation for
3 days, followed by measuring the phosphorylated H2AX
(γH2AX), a marker for DNA damage, as well as active
caspase-3, a marker for cellular apoptosis, by ﬂow cytometry and immunoblotting. As shown in Fig. 3a, b,
increased levels of γH2AX and caspase-3 were observed in
ICRF-193-treated CD4 T cells, indicating an increased
apoptosis-associated topological DNA damage in T cells
with Top2α inhibition.
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Fig. 2 Top2α inhibition induces CD4 T cell apoptosis and dysfunction. a Top2α levels in CD4 T cells treated with DMSO (con) or Top2α inhibitor
(ICRF-193) in the presence of anti-CD3/CD28 stimulation for 6, 24, 48, and 72 h, were determined by immunoblotting. b Top2α protein levels in CD4
T cells that were treated with DMSO (Cont) or Top2α inhibitor (ETP) with TCR (anti-CD3/CD28) stimulation for 6, 24, and 48 h. c Top2cc levels in
genomic DNA from CD4 T cells that were exposed to DMSO control or Top2α inhibitor (ICRF or ETP) for 72 h, were measured by immunoblotting.
d Representative dot plots and summary data of IL-2 and IFN-γ expression in TCR-stimulated CD4 T cells that were exposed to ETP or DMSO control.
e T cell proliferation, measured by CFSE dilution, in TCR-stimulated CD4 T cells in the presence of ICRF and DMSO control for 5 d. f Av and 7-AAD
staining of CD4 T cells that were treated with various concentrations of ICRF-193 for 1, 2, 3, and 5 days, determined by ﬂow cytometry. g The vulnerability
of CD4 T cells that were derived from viral infected individuals and HS to the ICRF-193-induced apoptosis, were determined by ﬂow cytometry.

Since telomeres play an important role in preserving
chromosome integrity and cell longevity30–33, we asked
whether Top2α can also function at telomeres to maintain
telomere integrity in proliferating T cells. To test this, we
examined Top2α expression in primary CD4 T cells with or
without TCR stimulation by microscopy. As shown in
Fig. 3c, the expression of Top2α was not detected in resting
primary CD4 T cells without TCR stimulation. Similar to
the immunoblot results (Fig. 2a), after stimulation with antiCD3/CD28 for 3 days, Top2α was detected in activated
T cells, as shown by positive Top2α immunoﬂuorescent
staining in the nuclei of larger, activated T cells upon
comparing the same bright-ﬁeld imaging. Notably, confocal
imaging from immunoﬂuorescence-ﬂorescence in situ
hybridization (IF-FISH) showed that Top2α colocalized
with a telomere probe (Tel-C-TAACCC) (Fig. 3d), suggesting a role for Top2α in maintaining telomere integrity.
Human telomeres consist of triple guanine repeats
(TTAGGG) that are sensitive to DNA damage34,35. We
hypothesized that Top2α inhibition-mediated genomic
DNA damage may affect telomeres as we have previously shown for telomere erosion in T cells derived
from virus-infected subjects5–9. To determine telomeric
Ofﬁcial journal of the Cell Death Differentiation Association

DNA damage in Top2 inhibitor-treated T cells, we
measured the number of dysfunctional telomereinduced foci (TIF, a hallmark of telomeric DNA
damage36,37) by examining the colocalization of 53BP1/
TRF1 (p53-binding protein 1/telomeric repeat-binding
factor 1) using confocal microscopy. As shown in Fig. 3e,
the number of TIFs per nucleus was signiﬁcantly
higher in CD4 T cells exposed to ICRF or ETP compared to vehicle control. These results suggest that
Top2α inhibition causes telomeric DNA damage and
cell apoptosis.
Top2α inhibition leads to telomere erosion via suppression
of shelterin TRF2 and telomerase activity

To determine whether Top2α inhibitor-treated T cells
mirror the telomere loss seen in patients with viral infections, we measured the telomere length in ICRF-treated
T cells by Flow-FISH. T cells treated with ICRF-193 in the
presence of TCR stimulation for 5 days showed signiﬁcantly
shorter telomeres compared to the control cells (Fig. 4a).
Telomeres are protected by shelterin proteins38,39. To
explore the mechanisms of telomere erosion, we examined the integrity of the telomeric shelterin complex in
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Fig. 3 Induction of telomeric DNA damage in CD4 T cells that were treated with Top2α inhibitors. a γH2AX levels in TCR-stimulated CD4
T cells treated with ICRF or DMSO control for 3 days, measured by ﬂow cytometry. b Active caspase-3 levels in TCR-stimulated CD4 T cells exposed
to ICRF or DMSO control for 3 days, measured by immunoblotting. c Top2α expression in TCR-activated CD4 T cells, determined by confocal
microscopy with white/dark and ﬂuorescent ﬁelds. d Colocalization of Top2α immunostaining with telomere probe signals in CD4 T cells, determined
by confocal microscopy. e Representative images and summary data of the dysfunctional telomere-induced foci (TIFs) per nucleus in TCR-stimulated
CD4 T cells exposed to ICRF, ETP, or DMSO control for 3 days, determined by confocal microscopy (n = number of subjects).

T cells exposed to the Top2α inhibitor ICRF-193. As
shown in Fig. 4b, among the shelterin proteins examined,
only telomeric repeat-binding factor 2 (TRF2) was signiﬁcantly inhibited. TRF1 was also slightly downregulated,
but TRF1-interacting nuclear protein 2 (TIN2) was
slightly upregulated, while telomere protection protein 1
(TPP1), repressor/activator protein 1 (RAP1), and protection of telomere 1 (POT1) remained unchanged. These
ﬁndings truly recapitulate the results we observed in CD4
T cells derived from HCV and/or HIV-infected
patients6,7. Since the primary functions of TRF2 are to
protect telomeres from unwanted DNA damage and to
recruit telomerase to telomeres, its inhibition may lead
to telomere uncapping or deprotection as well as telomerase deprivation from telomeres.
Telomeres are replenished by telomerase32,40,41. To
determine the role of telomerase in Top2α-mediated telomere inhibition, we measured the expression of human
telomerase reverse transcriptase (hTERT, the catalytic
subunit of telomerase) by RT-PCR and telomerase activities by a TRAP assay in ICRF-193-treated CD4 T cells. As
shown in Fig. 4c, ICRF treatment did not change hTERT
expression, but remarkably inhibited telomerase activity,
which again recapitulated our ﬁndings in T cells from
patients with HCV or HIV infection.
Ofﬁcial journal of the Cell Death Differentiation Association

Top2α-mediated topological DDR involves dynamic
activation and depletion of DNA repair kinases

DNA damage activates the protein kinase ataxiatelangiectasia mutated (ATM), an enzyme involved in
repairing double-strand breaks (DSB) for cell survival42–44.
To determine whether ATM is involved in Top2α-mediated
topological DDR, we examined the expression kinetics of
ATM in CD4 T cells following ICRF treatments. As shown
in Fig. 4d, ATM increased in response to DDR in the early
phase (6–24 h) and then gradually diminished with longer
ICRF-193 treatments (48–72 h). These results indicate that
ICRF-193-induced, Top2α-mediated topological DDR
involves dynamic activation and depletion of ATM. These
are in line with our recent ﬁndings of ATM dynamics in
healthy CD4 T cells treated with KML001 or Top1 inhibitor8,9 and in CD4 T cells derived from patients with
chronic HCV and/or HIV infection5–7.
Top2α-mediated Top2cc accumulation and DDR involves
PARP1 induction and TDP2 inhibition

Top2α relaxes intertwined DNA by producing Top2cc,
which can be trapped at enzyme-DNA crosslinks and
causes PDB, whose removal depends on the tyrosyl-DNA
phosphodiesterase-2 (TDP2) pathway21,22,45. Notably,
Top1cc excision by TDP1 requires Poly ADP-Ribose
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Fig. 4 Top2α inhibition induces telomere erosion via suppressing shelterin proteins, telomerase activity, ATM, and TDP2. a Telomere length
(measured by Flow-FISH) in CD4 T cells treated with ICRF-193 or DMSO control for 5 days. b Shelterin proteins (measured by immunoblotting) in CD4
T cells treated with or without ICRF-193. c hTERT expression (measured by RT-qPCR) and telomerase activity (measured by TRAP assay) in CD4 T cells
treated with or without ICRF. d ATM expression (measured by immunoblotting) in TCR-stimulated CD4 T cells exposed to ICRF, or DMSO control for 6,
24, 48, and 72 h. e Cleaved PARP1 levels in TCR-activated CD4 T cells exposed to ICRF or DMSO for 72 h. f TDP2 expression in TCR-activated CD4
T cells treated with ICRF or DMSO for 72 h. g TDP2 expressions in CD4 T cells isolated from HS and chronically HBV-, HCV-, or HIV-infected individuals.

Polymerase 1 (PARP1), an enzyme that catalyzes the
transfer of ADP-ribose onto target proteins and plays an
important role in cell apoptosis, DNA repair, and chromosomal stability46,47. Speciﬁcally, PARP1 binds to and
PARylates TDP1, leading to TDP1 stabilization and its
recruitment at the sites of Top1cc-PDB to initiate the
repair process47,48. Whether PARP1 is involved in the
TDP2-mediated Top2cc-PDB repair remains unknown.
To determine whether Top2α inhibitor-induced DNA
damage in T cells involves TDP2 suppression and PARP1
induction, we measured PARP1 and TDP2 in ICRFtreated CD4 T cells. As shown in Fig. 4e, f, the cleaved
form of PARP1 was markedly induced while TDP2 was
reduced by the treatment with Top2α inhibitor. Notably,
TDP2 levels were also signiﬁcantly inhibited in CD4
T cells derived from HBV, HCV, and HIV-infected subjects (Fig. 4g), which are consistent with the data above
showing Top2α inhibition, Top2cc accumulation, PARP1
induction, and apoptosis in these cells (Figs. 1–4)5–9.
We next assessed whether inhibition of PARP1 could
increase DNA damage in ETP-treated T cells. As shown
in Fig. 5a, compared to the DMSO-treated control (lane
1), ETP treatment (lane 2) inhibited Top2α and TDP2
expressions, but increased the cleaved form of PARP1.
Ofﬁcial journal of the Cell Death Differentiation Association

Notably, the PARP1 inhibitor (ABT-888)49 diminished
Top2α and TDP2 expressions, but increased PARP1
cleavage in DMSO-treated cells (lane 3) as well as in ETPtreated cells (lane 4), suggesting that PARP1 is involved in
the ETP-mediated Top2α inhibition and TDP2-mediated
DNA repair pathway.
We further hypothesized that Top2cc-mediated transcription blockade may trigger Top2α protein degradation
by an ubiquitin-mediated mechanism. To test this
hypothesis, we examined whether the ubiquitin degradation machinery could contribute to the observed Top2α
protein inhibition and DNA damage-mediated apoptosis.
As shown in Fig. 5b, compared to the control (lane 1),
ETP treatment decreased Top2α and TDP2 but increased
the PARP1 levels (lane 2). Intriguingly, inhibition of ubiquitin by the isopeptidase inhibitor (G5), which causes
depletion of free nuclear ubiquitin50, prevented Top2α
and TDP2 degradation in DMSO-treated cells (lane 3),
especially in ETP-treated T cells (lane 4). We also investigated whether inhibition of the ubiquitin system
could prevent DDR-mediated cell apoptosis. Treatment
with G5 prevented further induction of PARP1 in ETPexposed cells (lane 4) compared to DMSO-treated control
(line 3) and ETP-treated cells (lane 2), although G5
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Fig. 5 PARP1 and TDP2 are involved in the Top2α-mediated DNA damage and cell apoptosis. a Immunoblotting of Top2α, TDP2, and PARP1
expressions in TCR-activated CD4 T cells in the presence or absence of Top2α inhibitor (ETP) or PARP inhibitor (ABT-888). b Immunoblotting of Top2α,
TDP2, and PARP1 expressions in TCR-stimulated CD4 T cells with or without ETP treatment in the presence or absence of ubiquitin isopeptidase
inhibitor (G5). c Immunoblotting of Top2α, TDP2, and PARP1 expressions in TCR-activated CD4 T cells with or without ETP treatment in the presence
or absence of proteasomal inhibitor (MG132). d Immunoblotting of TDP2 and Top2α expressions in TCR-activated CD4 T cells exposed to TDP2
inhibitor (ZW-1226) for 3 days. e Flow cytometric analysis of percentages (%) of γH2AX+ cells within TCR-activated CD4 T cells treated with TDP2
inhibitor (5 μM) or DMSO control for 3 days. f–h Flow cytometric analysis of percentage (%) of Av+, IL-2+, and IFN-γ+ cells within TCR-activated CD4
T cells treated with TDP2 inhibitor (2 μM, 5 μM) or DMSO control for 3 days.

treatment alone (lane 3) increased level of cleaved PARP1
compared to cells exposed to DMSO (lane 1). Similarly,
inhibition of proteolysis by the proteasome inhibitor
MG132, which prevented ETP-induced Top2α and TDP2
degradation, also prevented ETP-induced accumulation of
PARP1 (Fig. 5c), suggesting that topological DNA damage
depends on Top2α and TDP2 ubiquitination and proteasome degradation. Taken together, these results suggest that the ubiquitin-mediated proteolysis of Top2α and
TDP2 is involved in the ETP-induced topological DNA
damage.
TDP2 inhibition promotes CD4 T cell apoptosis and
dysfunction

Since Top2α-mediated topological DNA damage can be
repaired by TDP2, which is also inhibited in CD4 T cells
treated with Top2α inhibitor in vitro and isolated from
virally infected patients in vivo (Fig. 4), we next determined the effect of the TDP2 inhibitor ZW-1226 on T cell
survival and functions. ZW-1266 is a cell-permeable
deazaﬂavin analog that selectively inhibits TDP2 activity
and sensitizes cancer cells toward ETP-treatment51. While
this drug did not affect the expression levels of TDP2 and
Ofﬁcial journal of the Cell Death Differentiation Association

Top2α in TCR-activated CD4 T cells (Fig. 5d), TDP2
inhibition resulted in an increased level of γH2AX and Av
staining, and decreased intracellular IL-2 and IFN-γ
production (Fig. 5e–h), suggesting that TDP2 is important
for maintaining Top2α-mediated T cell DNA topology
and cellular functions.

Discussion
T cells play a pivotal role in controlling pathogenic
infection and vaccine responses. During chronic viral
infections, however, T cells are always dysregulated and
often non-responsive to vaccines1. We and others have
previously reported that T cells from chronically virusinfected individuals are prematurely aged due to accelerated telomere erosion1–17, but the underlying mechanisms
for T cell telomeric DNA damage remain unclear. Since
Top2α is required to remove DNA supercoiling generated
during cell proliferation, and Top2cc can become trapped
during gene transcription to cause Top2cc-linked PDB
due to TDP2 depletion21,22, we hypothesized that DNA
topology in T cells may be affected during viral infections
to trigger DDR as a mechanism of virus-induced immune
evasion, and thus, persistent infection.
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In the present study, we employed T cells isolated from
virus-infected individuals and primary T cells treated with
Top2α inhibitors as model to obtain molecular insights
into the mechanisms underlying Top2α-mediated DNA
damage and repair signaling. We demonstrated that: (1)
T cells derived from chronically virus-infected individuals
exhibit diminished Top2α enzyme expression and activity,
leading to accumulation of Top2cc and DNA damage,
including telomere erosion; (2) ETP or ICRF-induced
Top2α inhibition, topological DNA damage, telomere
uncapping and attrition, T cell apoptosis and dysfunctions
recapitulate the phenotype seen in T cells during chronic
viral (HBV, HCV, HIV) infections, highlighting the role of
Top2α in maintaining telomeric DNA integrity and
securing T cell survival or function; (3) Top2α inhibition
occurs at the post-transcriptional level (likely via the
ubiquitin-mediated proteolysis) and is related to
TDP2 suppression, PARP1 induction, and Top2cc accumulation; (4) Top2α inhibition-mediated telomeric DDR
involves telomere TRF2-uncapping, diminished telomerase activity, and a dynamic ATM activation followed by
deprivation; and (5) T cells from virally infected subjects
with lower Top2α levels are more vulnerable to Top2α
inhibitor-induced topological DNA damage and cell
apoptosis, indicating an important role for Top2α in
preventing unwanted DNA damage and securing cell
survival.
Although the accumulation of DNA damage and the
failure to repair it may affect cell survival and function,
the molecular signaling pathways in T lymphocytes in the
context of chronic viral infections are incompletely
understood. Top2α cuts both strands of the DNA helix
simultaneously in order to manage DNA entangles and
supercoils25. Once cut, the ends of the DNA are separated, a second DNA duplex is passed through the break,
and the cut DNA is then religated. This process allows the
Top2α to increase or decrease the linking numbers of a
DNA loop by two units and promotes chromosome
untying (Fig. 6a). Etoposide is a semisynthetic derivative
of podophyllotoxin that forms a ternary complex with
DNA and Top2α and prevents religation of the DNA
strands, and by doing so causes the DNA strands to break
(Fig. 6b)26. ICRF-193 is a bisdioxopiperazine Top2α catalytic inhibitor that blocks Top2α turnover by trapping it
in a closed clamp conformation and delays the cell cycle
progression from metaphase in mammalian cells (Fig. 6c),
likely with the ability to damage DNA and trap the DNATop2α crosslinking complex27. ZW-1266 is a cellpermeable deazaﬂavin analog (Fig. 6d) that selectively
inhibits TDP2, but not TDP1 enzymatic activity in vitro,
and strongly sensitizes cancer cells toward the treatment
of ETP, a phenotype consistent with the TDP2 function
loss and leads to the Top2cc formation51. Cancer cells and
highly proliferative T cells rely on Top2α more than other
Ofﬁcial journal of the Cell Death Differentiation Association
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cells, because they divide more rapidly. Therefore, deﬁciency or inhibition of this enzyme causes errors in DNA
topology and promotes cell apoptosis. Our results, in
conjunction with our previous reports5–9, support a
model (depicted in Fig. 6e), in which Top2α inhibition
and Top2cc accumulation block transcription elongation,
which triggers the ubiquitin-mediated Top2α proteolysis
and the generation of Top2cc-mediated PDBs. Defective
repair of these PDBs by the DNA repair machineries such
as TDP2 can lead to more DDR, which activates ATM
kinase and phosphorylation of its downstream substrates
such as CHK2 and p53. Activated ATM also activates
53BP1 and γH2AX assembly into nuclear DNA damage
foci and promotes the ubiquitination of multiple signaling
molecules in the process of DNA damage and repair.
Notably, several E3 ligases have been reported for Top2α
ubiquitination and proteasomal degradation45. Our ﬁndings that Top2α and TDP2 inhibitions, as well as γH2AX
and PARP1 inductions in treated T cells, depend on
Top2α ubiquitination suggest that they arise during the
repair of Top2cc, and this pathway feeds back to enhance
Top2cc repair after Top2α-linked PDB induction. Moreover, it appears that PARP1 is involved not only in the
process of TDP1-mediated excision of Top1cc47,48, but
also in TDP2-mediated repair of Top2cc, since PARP1
inhibition alters Top2α-PDB induction following Top2cc
stabilization. This Top2 model, similar to our Top1
model9, is supported by our recent ﬁndings showing that
ATM deﬁciency5,7, TRF2 uncapping6, and telomere targeting8 promote telomeric DNA damage and T cell
senescence and apoptosis, as demonstrated in this study
in T cells isolated from chronic viral infections or T cells
treated with Top2α inhibitors.
While the mechanisms leading to Top2α inhibition
during chronic viral infections remain unclear, multiple
factors may play a role. Topological DNA damage might
occur in proliferating T cells under physiological conditions, but Top2cc can be trapped under a broad range of
pathological conditions, including Top2α inhibition by
immuno-modulating viruses (HBV, HCV, and HIV),
oxidative base damage by alkylation with carcinogenic
compounds or antiviral agents, and ribonucleotide
misincorporations during genetic activities in overexpanding T cells in response to low-grade chronic
inﬂammation18–23. Therefore, these Top2α-linked PDBs
may have a signiﬁcant impact on replicative T cells,
leading to reprogramming of the DDR and remodeling of
T cell fate that arise from the defective removal of Top2cc
due to deprivation of TDP2, deprotection of telomeres by
shelterins6, failure of telomere elongation by telomerase,
and deﬁciency of DNA damage repair by ATM5,7. T cells
may particularly be prone and vulnerable to Top2αmediated topological DNA damage and cell apoptosis as a
result of high rates of cell turnover and oxygen
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Fig. 6 A working model for virus-induced disruption of DNA topology and in T cell dysregulation. a A schematic representation of Top2α on
the supercoiled, catenated chromosomal DNA. Top2α cuts both strands of the DNA helix in order to manage DNA tangles and supercoils. Once cut,
the ends of the DNA are separated, a second DNA duplex is passed through the break, and the cut DNA is then religated. This process allows Top2α
to increase or decrease the linking number of a DNA loop by 2 units, and thus promotes chromosome disentanglement. b, c A schematic
representation showing ETP or ICRF in the Top2α-DNA crosslinks. Etoposide is a semisynthetic derivative of podophyllotoxin that forms a ternary
complex with DNA and Top2α, and prevents religation of the DNA strands, causing DNA strand breaks. ICRF-193 poisons DNA-Top2α crosslinking
complexes and delays cell cycle progression to mitosis. d Structure of ZW-1226, a TDP2 functional inhibitor. e A schematic model of Top2α-mediated
telomeric DDR and T cell dysregulation during chronic viral infection. The intertwined nature of two complementary DNA strands often leads to
topological entanglements during DNA replication, transcription, and recombination that must be resolved to ensure normal DNA transactions and
cell functions. In order to prevent and correct these types of topological problems, Top2α binds to DNA and cut two DNA strands simultaneously,
allowing the DNA to be untangled or unwound. Based on our ﬁndings, the immunomodulatory virus (HBV, HCV, HIV) infection and/or ROSgenerating inﬂammation can inhibit Top2α protein expression and enzyme activity, leading to Top2cc becoming trapped at the DNA break sites
including telomere termini, and causing topological DNA damage, telomere loss, cell senescence, and apoptosis. This continuous regulatory cascade
represents a novel molecular mechanism underlying CD4 T cell dysfunction, which contributes to the viral persistence and vaccine nonresponsiveness in human viral infections.

consumption, which produce large amounts of reactive
oxygen species (ROS) that we have recently shown signiﬁcantly elevated in T cells from viral (HCV and HIV)
infected individuals5–7. Indeed, ROS can stabilize Top2cc
to cause topological DNA damage and activate the ATM
signaling pathway52. Thus, our ﬁndings suggest a new
concept in which topological DNA damage contributes to
T cell senescence, apoptosis, and immune evasion during
chronic viral infections.
It should be pointed out that while Top2α inhibition
and Top2cc accumulation explain both telomeric DNA
damage and cell apoptosis, they may also function as a
double-edged sword that can result in both overwhelming
cell death storm in acute infection and immune tolerance
or immune suppression in chronic infection1. Nevertheless, these novel ﬁndings demonstrate, for the ﬁrst
time, the role of Top2α in DDR and shed light on the
molecular aspects of immunomodulation during human
Ofﬁcial journal of the Cell Death Differentiation Association

viral infections. Most importantly, this study provides a
potential strategy for restoring impaired DNA topological
machinery as a mean to improve T cell functions and
vaccine responses against human viral diseases.

Materials and methods
Subjects

The study protocol was approved by the institutional
review board (IRB) of East Tennessee State University and
James H. Quillen VA Medical Center (ETSU/VA IRB,
Johnson City, TN). Written informed consent was
obtained from all subjects. The study subjects were
composed of four populations: 27 chronically HBVinfected patients on antiviral treatment with undetectable viremia (HBV-DNA); 42 chronically HCV-infected
patients prior to antiviral therapy; 56 latently HIVinfected patients on antiretroviral therapy (ART) with
undetectable viremia (HIV-RNA); and 105 age-matched
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Table 1 Demographic information of the study participants.
Subjects

Numbers

Age (Mean)

Gender (M/F)

Viral load and other characteristics

HCV

42

29–68 (48)

36/6

135–6,696,048 IU/ml, 32 GT1, 6 GT2, 4 GT3

HBV

27

29–72 (42)

22/5

All on antivirals with undetectable HBV-DNA

HIV

56

22–70 (48)

46/10

All on ART with undetectable HIV-RNA

HS

105

21–65 (46)

75/30

All tested negative for HCV, HBV, and HIV

Table 2 Primer sequences used in real-time RT-PCR of this study.
Primers

Forward

Reverse

hTERT

5′-CCAAGTTCCTGCACTGGCTGA-3′

5′-TTCCCGATGCTGCCTGACC-3′

Top2α

5′-ACCATTGCAGCCTGTAAATGA-3’

5′-GGGCGGAGCAAAATATGTTCC-3’

GAPDH

5′-TGCACCACCAACTGCTTAGC-3′

5′-GGCATGGACTGTGGTCATGAG-3′

healthy subjects (HS). HS blood samples were provided by
Physicians Plasma Alliance (PPA), Gray, TN, and were
negative for HBV, HCV, and HIV infections. The characteristics of the subjects recruited in this study are
described in Table 1.
Cell isolation and culture

Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood by Ficoll density centrifugation
(GE Healthcare, Piscataway, NJ). The CD4+ T cells were
isolated from PBMCs using the CD4+ T Cell Negative
Selection Kit and a MidiMACS™ Separator (Miltenyi
Biotec Inc., Auburn, CA). The cells were cultured in
RPMI-1640 medium supplemented with 10% FBS
(Atlanta Biologicals, Flowery Branch, GA), 100 IU/ml
penicillin, and 2 mM L-glutamine (Thermo Scientiﬁc,
Logan, Utah) and maintained at 37 °C and 5% CO2
atmosphere.
Flow cytometry

Intracellular IL-2, IFN-γ cytokine production, DNA
damage marker γH2AX expression, CSFE-label CD4 T cell
proliferation, telomere length measured by Flow-FISH,
and cell apoptosis assay for Av/7AAD expression were
analyzed by ﬂow cytometry, as described previously5–7.
The following reagents were used in the assays: PElabelled Av, 7-AAD, IL-2, IFN-γ, γH2AX (BD), CD4Alexa-647 (Bio legend), telomere probe Tel-C (TAACCC)FITC (0.25 µg probe/mL, PNA Bio, Newbury Park, CA).
RNA isolation and real-time RT-PCR

Total RNA was extracted from 1 × 106 CD4 T cells
using the PureLink RNA Mini Kit (Invitrogen, Carlsbad,
Ofﬁcial journal of the Cell Death Differentiation Association

CA), and cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Bio-systems,
Foster City, CA) per the manufacturer’s instruction.
Quantitative RT-PCR was performed in triplicate as
described previously5–7. Gene expression levels were
determined using the 2-ΔΔct method. Values were normalized to the GAPDH level and are presented as
fold changes. The PCR primer sequences are shown in
Table 2.
Immunoblotting

Since Top2α is only expressed in activated T cells, we
examined Top2α level in puriﬁed CD4 T cells activated
with anti-CD3/CD28 for 3 days by immunoblotting.
Brieﬂy, CD4 T cells (2 × 106) were puriﬁed from HCV,
HBV, or HIV patients and HS as described previously9.
Primary and secondary antibodies included Top2α,
PARP1, TRF1, TRF2, TPP1, TIN2, RAP1, POT1, ATM,
GAPDH, β-actin, and horseradish peroxide-conjugated
antibody (Cell Signaling). Images were captured using
ChemiDoc™ XRS + System (Bio-Rad). Protein band intensity was quantitated by the Image Lab software (Bio-Rad).
Top2α activity assay

The activity of Top2α was measured using the Topoisomerase II Assay Kit (Cat #TG1001; Topogen Inc; Buena
Vista, CO). Brieﬂy, CD4 T cells were isolated, and cell
extracts were prepared according to the manufacturer’s
instructions. Because nuclease activity may cause some
degradation of the kDNA substrate and generate a smear
of degradation products, we used a Top2α isolation kit to
purify the nuclear extract. The puriﬁed extract was mixed
with plasmid DNA substrate and reaction buffer for
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30 min at 37 °C, loaded to a 1% agarose gel with loading
dye and then subjected to electrophoresis for 2 h at
5–10 V/cm before illuminating with a UV transilluminator. The intensity of the relaxed circular DNA was
measured by densitometry.
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Top2cc detection

Top2cc was detected using the Human Topoisomerase
ICE Assay Kit (Cat #TG1020-2a; Topogen). The method
of DNA puriﬁcation was modiﬁed by combining the ICE
Assay Kit and PureLink™ Genomic DNA Mini Kit (Cat
#K182001; Thermo Fisher Scientiﬁc, Waltham, MA).
Brieﬂy, genomic DNA samples were extracted from cell
pellets using buffers from the ICE assay kit and then
puriﬁed by the column of PureLink™ Genomic DNA Mini
Kit. The DNA samples were loaded onto NC membrane
by a vacuum pump and were incubated with primary antiTop2cc antibody from the ICE assay kit, followed by
western blotting as described above.
Confocal microscopy

CD4 T cells were isolated and cultured as described
above, followed by immunoﬂuorescence staining using a
method described previously6. The primary antibodies
included Rabbit anti-53BP1, and mouse TRF1 (Thermo
Fisher). The secondary antibodies included anti-rabbit
IgG-Alexa Fluor 488 and anti-mouse IgG-Alexa Fluor 555
(Invitrogen). We also used Tel-C (TAACCC)-FITC probe
for telomere staining. The cells were washed and mounted
with DAPI Fluoromount-G (SouthernBiotech, Birmingham, AL). Images were acquired with a confocal laserscanning inverted microscope (Leica Confocal, Model
TCS sp8, Germany).
Statistics

The data were analyzed using Prism 7 software and are
presented as mean ± SEM. Differences between two
groups were analyzed by independent Student’s t-test or
paired t-test. P-values of <0.05, or <0.01 were considered
statistically signiﬁcant or very signiﬁcant, respectively.
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